Cargando…
Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968902/ https://www.ncbi.nlm.nih.gov/pubmed/34937320 http://dx.doi.org/10.3324/haematol.2021.280061 |
| _version_ | 1784679143607107584 |
|---|---|
| author | Allan, John N. Pinilla-Ibarz, Javier Gladstone, Douglas E. Patel, Krish Sharman, Jeff P. Wierda, William G. Choi, Michael Y. O’Brien, Susan M. Shadman, Mazyar Davids, Matthew S. Pagel, John M. Yimer, Habte A. Ward, Renee Acton, Gary Taverna, Pietro Combs, Daniel L. Fox, Judith A. Furman, Richard R. Brown, Jennifer R. |
| author_facet | Allan, John N. Pinilla-Ibarz, Javier Gladstone, Douglas E. Patel, Krish Sharman, Jeff P. Wierda, William G. Choi, Michael Y. O’Brien, Susan M. Shadman, Mazyar Davids, Matthew S. Pagel, John M. Yimer, Habte A. Ward, Renee Acton, Gary Taverna, Pietro Combs, Daniel L. Fox, Judith A. Furman, Richard R. Brown, Jennifer R. |
| author_sort | Allan, John N. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8968902 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89689022022-04-11 Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies Allan, John N. Pinilla-Ibarz, Javier Gladstone, Douglas E. Patel, Krish Sharman, Jeff P. Wierda, William G. Choi, Michael Y. O’Brien, Susan M. Shadman, Mazyar Davids, Matthew S. Pagel, John M. Yimer, Habte A. Ward, Renee Acton, Gary Taverna, Pietro Combs, Daniel L. Fox, Judith A. Furman, Richard R. Brown, Jennifer R. Haematologica Letters to the Editor Fondazione Ferrata Storti 2021-12-23 /pmc/articles/PMC8968902/ /pubmed/34937320 http://dx.doi.org/10.3324/haematol.2021.280061 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Allan, John N. Pinilla-Ibarz, Javier Gladstone, Douglas E. Patel, Krish Sharman, Jeff P. Wierda, William G. Choi, Michael Y. O’Brien, Susan M. Shadman, Mazyar Davids, Matthew S. Pagel, John M. Yimer, Habte A. Ward, Renee Acton, Gary Taverna, Pietro Combs, Daniel L. Fox, Judith A. Furman, Richard R. Brown, Jennifer R. Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies |
| title | Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies |
| title_full | Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies |
| title_fullStr | Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies |
| title_full_unstemmed | Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies |
| title_short | Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies |
| title_sort | phase ib dose-escalation study of the selective, noncovalent, reversible bruton’s tyrosine kinase inhibitor vecabrutinib in b-cell malignancies |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968902/ https://www.ncbi.nlm.nih.gov/pubmed/34937320 http://dx.doi.org/10.3324/haematol.2021.280061 |
| work_keys_str_mv | AT allanjohnn phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT pinillaibarzjavier phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT gladstonedouglase phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT patelkrish phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT sharmanjeffp phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT wierdawilliamg phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT choimichaely phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT obriensusanm phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT shadmanmazyar phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT davidsmatthews phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT pageljohnm phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT yimerhabtea phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT wardrenee phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT actongary phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT tavernapietro phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT combsdaniell phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT foxjuditha phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT furmanrichardr phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies AT brownjenniferr phaseibdoseescalationstudyoftheselectivenoncovalentreversiblebrutonstyrosinekinaseinhibitorvecabrutinibinbcellmalignancies |